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Ceftriaxone is a third-generation cephalosporin widely 
used in the treatment of many severe infections, 
including meningitis and pneumonia. Life-threatening 
complications of ceftriaxone therapy are very rare. 
Although a positive Coombs’ reaction occurs in 3% of 
patients with earlier cephalosporins [I], hemolytic 
anemia is very rare. However, in recent years, the 
number of cases of hemolytic anemia attributable to 
third-generation cephalosporins, including ceftriaxone, 
have increased [2-4]. We present an apparently immuno- 
competent adult case with hemolytic anemia with a 
fatal outcome caused by ceftriaxone. 
A 38-year-old man with no known disease was 
admitted to the emergency department in December 
1997 because of the rapid development of distur- 
bance of consciousness. Four days before admission, he 
suffered fever, anorexia, chills and headache. A diag- 
nosis of sinusitis was made, and he was prescribed oral 
amoxycillin-clavulanate. On the fourth day of the 
treatment, he was brought to the emergency depart- 
ment with a history of recent agitation and generalized 
convulsion. On physical examination, the patient was 
found to be comatose and unresponsive to sound. 
Nuchal rigidity and other meningeal findings were 
present. There was no rash. His temperature was 38.5”C. 
The initial laboratory studies revealed the following 
values: hemoglobin 13 g/dL; hematocrit 48%; leuko- 
cyte count 17 O O O / m m 3  (85% neutrophils); platelet 
count 230 O O O / m m 3 ;  serum aspartate aminotransferase 
(AST) 68 U/L; and serum alanine aminotransferase 
(ALT) 48 U/L. Bilirubin levels were normal. Com- 
puted tomographic scan of the brain was normal. 
Cerebrospinal fluid (CSF) was purulent: protein 148 
mg/dL, glucose (CSF/serum) 57/158 mg/dL, neutro- 
phils 830/mm3, and lymphocytes 70/mm3. Findings 
resembled those of purulent meningitis, and therapy 
with ceftriaxone (2 g IV every 12 h) was initiated em- 
pirically. No other therapeutic agents were used. No 
etiologic agent was identified by culture of blood and 
CSF, or by Gram-staining of the CSE The patient’s 
condition improved clinically, and on the third day 
of the ceftriaxone therapy the patient recovered and 
general physical findings were normal. His leukocyte 
count, serum AST and serum ALT levels decreased to 
normal limits. On the seventh day, CSF findings were 
near to normal limits: protein 52 mg/dL, glucose 
(CSF/serum) 64/139 mg/dL, lymphocytes 180/mm3 
and neutrophils 10/mm3. 
On the tenth day of therapy, icterus of the patient 
was noted. On physical examination he was quite well 
but a 3-cm, soft, blunt-edged hepatomegaly was pal- 
pated. Findings were as follows: hematocrit 31%; 
hemoglobin 7.2 g/dL; leukocyte 22 OOO/mm3; blood 
urea nitrogen (BUN) 60 mg/dL; creatinine 1.4 mg/dL; 
AST 263 U/L; ALT 293 U/L; total bilirubin 20.6 
mg/dL; indirect bilirubin 11.5 mg/dL; and direct 
bilirubin 9.1 mg/dL. A peripheral blood smear showed 
rouleaux formation and significant anisocytosis, and so 
ceftriaxone therapy was stopped. On day 11, anorexia, 
nausea and vomiting started. Diuresis was 50 mL/day. 
Hemoglobin and hematocrit decreased to 5.1 g/dL and 
13% respectively; the leukocyte count increased to 
36 800/mm3. BUN was 123 mg/dL, creatinine was 
2.52 mg/dL, platelet count was 189 O O O / m m 3 ,  total 
bilirubin was 30.9 mg/dL, and indirect bilirubin was 
17.2 mg/dL. Direct anti-globulin (Coombs’) test was 
positive. Abdominal ultrasonography showed diffuse 
enlargement of liver and spleen. Prednisolone 100 
mg/day was started together with forced diuresis. 
On  day 12, dyspnea, tachypnea and disturbance of 
consciousness developed. Creatinine increased to 7.8 
mg/dL. Total bilirubin level increased up to 140 mg/dL 
on the following days. Despite vigorous resuscitative 
efforts, including intensive care support, hernodialysis 
and hemofdtration, the patient died with evidence of 
multiple organ failure on day 15. 
Drug-induced hemolytic anemia in adults may 
be associated with immune reactions. Cephalosporins 
frequently interact with erythrocyte membranes non- 
specifically and result in a positive direct anti-globulin 
test, but hemolysis is rare. The pathogenic mechanisms 
of drug-induced hemolytic anemia can be divided into 
three groups: (1) the drug adsorption type; (2) the 
immune complex type; and (3) the autoantibody type 
[5]. Only the first two mechanisms cause massive 
hemolysis. The first one is also called the ‘penicillin 
type’, where antibody interacts with erythrocytes 
coated with drug after the injection of the drug, and 
hemolysis occurs extravascularly. Massive hemolysis 
may develop and the patient may die in a very short 
time. The patient may not become jaundiced, as there 
is little time for the breakdown of hemoglobin to 
bilirubin [4]. In the ‘immune complex mechanism’ 
type, the drug causes an IgM-type immune response, 
resulting in antigen-antibody complexes which bind to 
erythrocytes and activate the complement cascade. This 
usually leads to acute severe intravascular hemolysis, 
and sometimes shock and renal failure may develop [6]. 
If there is no previous use of the drug, it takes 7-10 
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days to develop, as in this case [7,8]. An IgM antibody 
dlrected against ceftriaxone has been one of the 
processes in third-generation cephalosporin-induced 
hemolysis [3,8]. The clinical course of our case, with a 
duration of 10 days between hemolysis and initiation of 
the ceftriaxone therapy, laboratory results and develop- 
ment of renal failure, suggests that the process was IgM- 
type immune complex mediated [3]. 
In all of the reported cases with hemolytic anemia 
induced by ceftriaxone, the patients were immuno- 
compromised in some way. The majority of the cases 
were children and had hematologic disorders such as 
sickle cell anemia. Many of them had been exposed to 
ceftriaxone previously [1,4] but this patient could not 
recall any previous cephalosporin therapy. He was 
apparently immunocompetent. He was hospitalized for 
the first time in his life, he was completely healthy and 
he had no recurrent infection or diarrhea. 
In this fatal complication of ceftriaxone therapy, 
no risk factors, such as repeated exposure to ceftriaxone 
or pre-existing hemolytic anemia, were identified. 
Although the patient had received amoxycillin- 
clavulanate immediately prior to receiving ceftriaxone, 
this is unlikely to have been a contributing factor, as 
very little of the prescribed dose was taken. Therefore, 
every patient receiving ceftriaxone, including those 
with no underlying disease, should be observed care- 
my. Drug-induced hemolytic anemia should always be 
considered in the dfferential diagnosis of intravascular 
hemolysis in patients receiving ceftriaxone and possibly 
other third-generation cephalosporins. 
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infection in two patients on chemotherapy 
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Nosocomial diarrhea, defined as the onset of diarrhea 
more than 72 h after admission, is most frequently 
associated with Clostridium d@cile infection or drug 
administration. Other enteropathogenic bacteria, 
although common in community-acquired diarrhea, 
are rarely involved. Routine stool cultures are therefore 
generally not required in the investigation of patients 
with nosocomial diarrhea, and some microbiological 
laboratories have implemented a rejection policy for 
such samples [l]. We report on two patients who 
presented with nosocomial salmonellosis during chemo- 
therapy-induced neutropenia. 
Patient A was a 37-year-old woman with a 2- 
year history of disseminated breast carcinoma, admitted 
on 2 January 1997 for chemotherapy and peripheral 
blood stem cell transplantation. She was assigned to a 
double room with a private lavatory. She had no 
complaints and reported one or two formed bowel 
movements per day. There was no history of overseas 
travel and there were no cases of diarrhea in her family. 
Her physical examination was unremarkable except for 
a mastectomy scar. Laboratory data on admission were: 
hemoglobin 102 g/L, leukocytes 8300/pL, platelets 
180 OOO/pL, and C-reactive protein (CRP) 1 mg/L 
(normal range < 8 mg/L). High-dose chemotherapy 
with cyclophosphamide (1500 mg/m2 per day), carbo- 
platin (200 mg/m2 per day) and thiotepa (125 mg/mz 
per day) was administered from 3 January to 5 January. 
Supportive therapy included co-trimoxazole (480 mg/ 
day PO), fluconazole (100 mg/day PO), omeprazole 
(40 mg/day PO) and metoclopramide. Peripheral 
blood stem cell transplantation was performed on 
8 January, and neutropenia developed on the following 
day. From 7 January to 9 January, she experienced self- 
limited diarrhea. Stool cultures and ELISAs for C. 
dijicile toxin taken on 8 January and 12 January were 
negative. On 13 January she developed pyrexia, 
followed the next day by abdominal cramps, watery 
diarrhea and a rise of CRE? Gram-negative sepsis was 
suspected and ceftazidime (2 g/8 h IV) given. A set of 
blood cultures taken on 14 January was negative, as was 
an ELISA for fecal C. d@cile toxin. A stool culture grew 
